Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.

Hong Y, Kowalski KG, Zhang J, Zhu L, Horga M, Bertz R, Pfister M, Roy A.

Antimicrob Agents Chemother. 2011 Dec;55(12):5746-52. doi: 10.1128/AAC.00554-11. Epub 2011 Sep 19.

2.

Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.

Schipani A, Dickinson L, Boffito M, Austin R, Owen A, Back D, Khoo S, Davies G.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):60-6. doi: 10.1097/QAI.0b013e3182737231.

3.

Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.

Foissac F, Blanche S, Dollfus C, Hirt D, Firtion G, Laurent C, Treluyer JM, Urien S.

Br J Clin Pharmacol. 2011 Dec;72(6):940-7. doi: 10.1111/j.1365-2125.2011.04035.x.

4.

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.

Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, Csajka C.

Antimicrob Agents Chemother. 2006 Nov;50(11):3801-8. Epub 2006 Aug 28.

5.

Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.

von Hentig N, Müller A, Rottmann C, Wolf T, Lutz T, Klauke S, Kurowski M, Oertel B, Dauer B, Harder S, Staszewski S.

Antimicrob Agents Chemother. 2007 Apr;51(4):1431-9. Epub 2007 Feb 12.

6.

Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.

Conradie F, Zorrilla C, Josipovic D, Botes M, Osiyemi O, Vandeloise E, Eley T, Child M, Bertz R, Hu W, Wirtz V, McGrath D.

HIV Med. 2011 Oct;12(9):570-9. doi: 10.1111/j.1468-1293.2011.00927.x. Epub 2011 May 16.

7.

Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.

Gianotti N, Seminari E, Guffanti M, Boeri E, Villani P, Regazzi M, Bigoloni A, Schira G, Tiberi S, Fusetti G, Lazzarin A, Castagna A.

New Microbiol. 2005 Apr;28(2):119-25.

PMID:
16035256
8.

Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system.

Fukushima K, Terasaka S, Haraya K, Kodera S, Seki Y, Wada A, Ito Y, Shibata N, Sugioka N, Takada K.

Biol Pharm Bull. 2007 Apr;30(4):733-8.

9.

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.

Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES study team.

AIDS. 2010 Aug 24;24(13):2019-27. doi: 10.1097/QAD.0b013e32833bee1b.

PMID:
20613461
10.

Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.

Pham PA, Flexner C, Parsons T, Vasist L, Fuchs E, Carson K, Agarwala S, Barditch-Crovo P.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):201-5.

PMID:
17414932
11.

Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.

Kreitchmann R, Best BM, Wang J, Stek A, Caparelli E, Watts DH, Smith E, Shapiro DE, Rossi S, Burchett SK, Hawkins E, Byroads M, Cressey TR, Mirochnick M.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):59-66. doi: 10.1097/QAI.0b013e318289b4d2.

12.

The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.

Winston A, Mallon PW, Satchell C, MacRae K, Williams KM, Schutz M, Law M, Cooper DA, Emery S.

Clin Infect Dis. 2007 Jun 1;44(11):1475-83. Epub 2007 Apr 18.

PMID:
17479946
13.

Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.

Kiser JJ, Rutstein RM, Samson P, Graham B, Aldrovandi G, Mofenson LM, Smith E, Schnittman S, Fenton T, Brundage RC, Fletcher CV.

AIDS. 2011 Jul 31;25(12):1489-96. doi: 10.1097/QAD.0b013e328348fc41.

14.

Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.

Ma Q, Gelbard HA, Maggirwar SB, Dewhurst S, Gendelman HE, Peterson DR, DiFrancesco R, Hochreiter JS, Morse GD, Schifitto G.

J Neurovirol. 2013 Jun;19(3):254-60. doi: 10.1007/s13365-013-0172-z. Epub 2013 Jun 5.

15.

Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

Moltó J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, Negredo E, Clotet B.

Ther Drug Monit. 2007 Oct;29(5):648-51.

PMID:
17898658
16.

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

Le Tiec C, Barrail A, Goujard C, Taburet AM.

Clin Pharmacokinet. 2005;44(10):1035-50. Review.

PMID:
16176117
17.

Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

Colombo S, Buclin T, Franc C, Guignard N, Khonkarly M, Tarr PE, Rochat B, Biollaz J, Telenti A, Decosterd LA, Cavassini M.

Antivir Ther. 2006;11(1):53-62.

PMID:
16518960
18.

Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.

Bunupuradah T, Techasaensiri C, Keadpudsa S, Thammajaruk N, Srimuan A, Sahakijpicharn T, Prasitsuebsai W, Ananworanich J, Puthanakit T; HIV-NAT 146 Study Team.

Pediatr Infect Dis J. 2014 Dec;33(12):e316-9. doi: 10.1097/INF.0000000000000469.

PMID:
24983717
19.

Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.

Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips DH, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES Study Team.

HIV Clin Trials. 2010 Mar-Apr;11(2):69-79. doi: 10.1310/hct1102-69.

PMID:
20542844
20.

Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.

Feldt T, Oette M, Kroidl A, Göbels K, Leidel R, Sagir A, Kuschak D, Häussinger D.

Eur J Med Res. 2005 Jan 28;10(1):7-10.

PMID:
15737947

Supplemental Content

Support Center